Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Biogen
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07483632CT.gov A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) | — | Not Yet Recruiting | — | — | — |
NCT05767736CT.gov A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS) | — | Active Not Recruiting | — | — | — |
NCT05658497CT.gov Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) | — | Recruiting | — | — | — |
NCT04948606CT.gov Exploring Diroximel Fumarate Real-world Experience in Canada and Israel | — | Terminated | — | — | — |
NCT05083923CT.gov A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS) | — | Completed | — | — | — |
NCT05688436CT.gov A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies | — | Active Not Recruiting | — | — | — |
NCT05000216CT.gov COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders | — | Terminated | — | — | — |
NCT04788615CT.gov Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS | — | Completed | — | — | — |
NCT04746976CT.gov Study of Diroximel Fumarate in the Real-World Setting | — | Terminated | — | — | — |
NCT04676204CT.gov Relationship Between Oral DMT Burden and Adherence in MS | — | Enrolling By Invitation | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Multiple Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Monomethyl Fumarate (this asset) | Biogen | P3 | BB · 64 |
| Fampridine | MGH Institute of Health Professions | P4 | BBB |
| Ocrelizumab | Polpharma Biologics International AG | P4 | BBB |
| Teriflunomide | Sanofi | P4 | BBB |
| Cladribine | University Hospital, Strasbourg, France | P4 | BBB |
| Nabiximols | Jazz Pharmaceuticals | P4 | BBB |
| Natalizumab | Biogen | P4 | BB |
| Interferon ?1 (Human Fibroblast Protein Moiety) | Bayer | P4 | BB |
| Methylphenidate | Johns Hopkins University | P3 | BB |
+42 more in the Multiple Sclerosis cohort
Other indications for Monomethyl Fumarate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Relapsing-Remitting Multiple Sclerosis | — | P1 | CCC · 52 |
| Schizophrenia | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Monomethyl Fumarate in Multiple Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/monomethyl-fumarate-multiple-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →